Ticker: NYSE: GSK, LSE: GSK
Headquarters: London, United Kingdom
Founded: 2000 (merger of Glaxo Wellcome and SmithKline Beecham)
CEO: Emma Walmsley
Market Cap: ~£70B (2026)
GlaxoSmithKline (GSK) is a global healthcare company headquartered in London, UK, with significant investments in neuroscience research. The company was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000, creating one of the world's largest pharmaceutical companies. GSK operates in three main divisions: Vaccines, Specialty Medicines, and General Medicines[1].
Under CEO Emma Walmsley, GSK has restructured its R&D approach, focusing on science-led differentiation in vaccines, immunology, and infectious diseases, while maintaining selective investments in neuroscience. The company has deliberately reduced its exposure to traditional CNS (central nervous system) drugs in favor of higher-margin specialty areas, though it maintains an active neuroscience pipeline with several programs in clinical development.
| Metric | Value |
|---|---|
| Market Cap | ~£70B (2026) |
| 2025 Revenue | ~£30B |
| R&D Budget | ~£5B annually |
| Employees | ~70,000 |
GSK has an active neuroscience division focused on multiple neurological and psychiatric conditions. While not as large as competitors like Biogen or Eli Lilly, GSK maintains strategic programs in high-need neurodegenerative and psychiatric indications[2].
| Drug | Indication | Mechanism | Phase |
|---|---|---|---|
| GSK-231 | Alzheimer's disease | Tau aggregation inhibitor | Phase 1 |
| GSK-452 | Alzheimer's disease | Amyloid-beta antibody | Phase 1 |
GSK's approach to Alzheimer's focuses on tau-targeted therapies, reflecting the company's view that amyloid-targeting approaches have shown limited efficacy. The tau aggregation inhibitor program represents a strategic bet on alternative mechanisms.
| Drug | Indication | Mechanism | Phase |
|---|---|---|---|
| GSK-123 | Parkinson's disease | LRRK2 inhibitor | Phase 1 |
The LRRK2 inhibitor program addresses the most common genetic cause of Parkinson's disease. GSK-123 targets the leucine-rich repeat kinase 2 protein, which is implicated in approximately 5-10% of familial Parkinson's cases.
GSK acquired Sirtris Pharmaceuticals in 2008 to develop SIRT1 activators for metabolic and aging-related diseases. Although the programs have shifted focus, the SIRT1 activator platform remains historically significant:
| Drug | Indication | Mechanism | Stage | Status |
|---|---|---|---|---|
| SRT2104 | Alzheimer's disease | SIRT1 activator | Phase 2 | Completed |
| SRT3025 | Neurodegeneration | SIRT1 activator | Phase 1 | Completed |
Key learnings from Sirtris programs:
See SIRT1 Activators for Parkinson's Disease for mechanism details.
| Drug | Indication | Mechanism | Phase |
|---|---|---|---|
| GSK-303 | ALS | SOD1 inhibitor | Phase 1 |
| GSK-445 | Depression | NMDA modulator | Phase 2 |
| GSK-567 | Schizophrenia | M4 agonist | Phase 2 |
GSK maintains active partnerships in neuroscience research:
GSK has historically been a major player in CNS drugs, though many key products have lost patent protection:
GSK's neuroscience strategy focuses on:
The company faces competition from specialized neuroscience companies like Biogen, Eli Lilly, and Roche in Alzheimer's, and from companies like Denali Therapeutics in Parkinson's.
GSK Annual Report 2025. Company Overview. 2025. ↩︎
GSK Pipeline. Neuroscience Programs. 2026. ↩︎